Werewolf Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Werewolf Therapeutics has a total shareholder equity of $89.4M and total debt of $25.6M, which brings its debt-to-equity ratio to 28.7%. Its total assets and total liabilities are $140.0M and $50.7M respectively.
Key information
28.7%
Debt to equity ratio
US$25.62m
Debt
| Interest coverage ratio | n/a |
| Cash | US$122.83m |
| Equity | US$89.38m |
| Total liabilities | US$50.66m |
| Total assets | US$140.04m |
Recent financial health updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24Recent updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Financial Position Analysis
Short Term Liabilities: HOWL's short term assets ($125.8M) exceed its short term liabilities ($12.5M).
Long Term Liabilities: HOWL's short term assets ($125.8M) exceed its long term liabilities ($38.2M).
Debt to Equity History and Analysis
Debt Level: HOWL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if HOWL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HOWL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HOWL has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 15.7% each year.